AJAmir Ghaffari Jolfayi

Amir Ghaffari Jolfayi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amir Ghaffari Jolfayi has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CT mitral valve calcium score and immediate outcomes after percutaneous transvenous mitral commissurotomy

    by Pooya Eini, Amir Ghaffari Jolfayi, Ata Firouzi, Farnaz Rafiee, Behnam Ranjbar, Raheleh Kaviani, Mozhgan Parsaee, Mohammad Javad Alemzadeh-Ansari, Hooman Bakhshandeh, Majid Maleki, et al.

  • Open Access

    Ischemic Heart Disease in the Middle East and North Africa, 1990–2021: An Integrated Analysis of Temporal Trends, Country‐Level Variation, SDI Patterns, and Risk Factors

    by Nahid Karamzad, Saeid Safiri, Amir Ghaffari Jolfayi, Seyed Ehsan Mousavi, Fatemeh Amiri, Mohammad Rahmanian, Mark J. M. Sullman, Ali‐Asghar Kolahi

    Background: Ischemic heart disease (IHD) remains a leading cause of mortality and disability worldwide. Using Global Burden of Disease (GBD) 2021 estimates, this study provides an integrated assessment of IHD burden across the Middle East and North Africa (MENA) region from 1990 to 2021, highlighting temporal trends, inter‐country heterogeneity, sociodemographic index (SDI)‐related patterns, and attributable risk factors by sex and age. Methods: We conducted a secondary analysis of GBD 2021 estimates for the 21 countries and territories in MENA. We assessed prevalence, deaths, and disability‐adjusted life years (DALYs), reporting counts and age‐standardized rates per 100,000 population with 95% uncertainty intervals (UIs). This framework allowed direct comparison of temporal change, cross‐country variation, development‐related gradients, and modifiable risk attribution within a single regional analysis. Results: In 2021, the age‐standardized prevalence of IHD in MENA was 6404.8 per 100,000 (95% UI: 5872.0–7041.1), with an age‐standardized mortality rate of 202.8 (95% UI: 180.6–223.7) and DALY rate of 4023.2 (95% UI: 3581.7–4507.5). Although age‐standardized death and DALY rates declined from 1990 to 2021, the burden remained substantial and unevenly distributed. Kuwait had the highest age‐standardized prevalence [7806.4 (95% UI: 7141.6–8556.3)] and Turkey the lowest [5365.9 (95% UI: 4895.5–5874.7)]. Saudi Arabia had the largest increase in age‐standardized prevalence [17.1% (95% UI: 11.4–23.0)], whereas Turkey had the largest decrease [−11.9% (95% UI: −17.3 to −6.9)]. DALY rates increased progressively with age for both sexes, and IHD burden showed an inverse, non‐linear relationship with SDI. The leading contributors to IHD DALYs were elevated systolic blood pressure [49.6%], elevated LDL cholesterol [39.6%], and exposure to ambient particulate matter pollution [28.2%]. Conclusion: Despite reductions in age‐standardized mortality and DALY rates, IHD remains a major public health challenge in MENA, with substantial cross‐country variation and a large contribution from modifiable risks. By integrating temporal trends, inter‐country heterogeneity, SDI‐related patterns, and attributable risk factors, this study provides novel evidence for prioritizing prevention efforts across the region. These findings support context‐specific prevention strategies prioritizing hypertension control, lipid management, and improved access to cardiovascular prevention and treatment, alongside action to reduce air pollution exposure; implementation should be tailored to national risk profiles, disease trends, and health‐system capacity.

  • Low‐Power Lasers Therapy Induced Mir‐143 Upregulation: A Novel Biomarker and Therapeutic Strategy for Restenosis

    by Atiyeh Asadi, Amir Ghafari Jolfayi, Rouhollah Karimzadeh, Mohammadreza Babaei, Maedeh Arabian

    Background: Coronary artery disease (CAD) remains a leading global cause of mortality, with percutaneous coronary intervention (PCI) being a primary treatment. However, in‐stent restenosis (ISR) affects 15%−30% of cases, driven by vascular injury, inflammation, and smooth muscle cell proliferation. While drug‐eluting stents reduce ISR rates, late complications persist. Low‐level laser therapy (LLLT) has emerged as a potential adjunctive treatment, modulating inflammation and cell behavior, but its effects on endothelial cells miRNA regulation remain unclear. Aims: This study investigated LLLT's impact on human umbilical vein endothelial cell (HUVEC) migration, proliferation, and miR‐143 expression, a key regulator and potential biomarker in vascular restenosis. Methods: HUVECs were cultured and exposed to 532 and 633 nm lasers at varying durations (10–200 s). Cell migration was assessed via scratch wound assays, with imaging at 1, 5‐, 12‐, 24‐, and 48‐h post‐irradiation. Proliferation and viability were quantified using image analysis (MATLAB). For gene expression, irradiated cells were incubated for 24 h, followed by RNA extraction, cDNA synthesis, and qRT‐PCR to measure miR‐143 levels. Results: The 532 nm laser inhibited HUVEC migration most effectively at 10 s, minimizing cytotoxicity. In contrast, the 633 nm laser required longer exposure (200 s) for comparable inhibition but induced delayed miR‐143 upregulation after 24 h, suggesting epigenetic modulation. Both wavelengths influenced cell behavior in a time‐ and dose‐dependent manner, with 532 nm offering rapid effects and 633 nm potentially exerting longer‐term genetic regulation. Conclusion: LLLT at specific wavelengths differentially modulates endothelial cell migration and miR‐143 expression, highlighting its potential as a non‐invasive strategy to mitigate restenosis. The 532 nm laser provides immediate anti‐migratory effects, while 633 nm may offer sustained benefits via miRNA regulation. Further research should optimize parameters and validate these findings in vivo to advance LLLT as a complementary therapy for vascular interventions.

  • Open Access

    Evaluating the Effect of Therapeutic Antibiotics in Prosthetic Joint Infections Culturing: A Narrative Review

    by Moein Zangiabadian, Mehrdad Jafari Tadi, Fateme Yousefimoghaddam, Ali Zangiabadian, Amir Ghaffari Jolfayi

    Background and Aims: One of the important complications of knee and hip replacement arthroplasty is prosthetic joint infection (PJI), which is usually accompanied by negative culture that leads to severe consequences compared to positive ones. This study aims to evaluate the arbitrary use or mistreatment of antibiotics for therapeutic purposes before the final diagnosis of PJI and its effect on the culture result and the process of diagnosis and treatment of these infections. Method: A comprehensive search was performed in PubMed/MEDLINE, EMBASE, and Scopus using the following keywords: “PJI,” “Antibiotic therapy,” “False negative,” and “Culture.” We included clinical trials, cohort, case‐control, and cross‐sectional studies written in English. Results: Among the nine reviewed studies, all mentioned the therapeutic use of antibiotics as an important reason for negative culture results in PJI. Five studies examined the minimum recommended time for discontinuing antibiotic therapy, which varied from 4 days to 3 months. Four studies evaluated the type and dosage of antibiotics, and one study discussed the effect of antibiotics on tissue‐infecting microorganisms. Conclusion: Using antibiotics for therapeutic purposes is the leading cause of false‐negative cultures in joint prosthesis infections, which reduces the sensitivity of the culture in different ways, such as bacterial biofilm formation. Discontinuing antibiotics at least 2 weeks before sampling can help increase the sensitivity of the culturing. More studies should be done on other factors related to the effect of antibiotics on culture results, including the type of antibiotic and microorganism. With the available data, it can only be said that beta‐lactams are the most common antibiotics used as therapeutic agents, leading to negative culture results. According to the Al‐Mayahi study, therapeutic antibiotics increase the possibility of non‐fermenting Gram‐negative bacteria growth.


  • Open Access

    Comparison of Hospital Outcomes of Patients Who Undergo Urgent CABG Compared to Patients Who Undergo Elective CABG

    by Amir Ghaffari Jolfayi, Nima Taheri, Zahra Hosseini, Arezoo Rezaei, Atefeh Kashanizadeh, Zahra Amir Sardari, Erfan Kohansal, Amir Askarinejad, Ali Mohammad Nasirian, Mansoor Namazi, et al.

    Background: Coronary artery bypass grafting (CABG) is one of the most common cardiac surgeries worldwide. Whether performed electively or urgently, CABG is associated with significant differences in postoperative outcomes. Urgent CABG is associated with higher postoperative morbidity and mortality, often influenced by preoperative cardiac risk factors. This study compares the demographics, clinical characteristics, and outcomes of patients undergoing urgent versus elective CABG. Methods: This retrospective study analyzed data from 4872 patients who underwent CABG between 2019 and 2022 at Rajaie Cardiovascular Medical and Research Institute. Urgent CABG was defined as surgery performed within 24–72 h (mostly within 48 h) of a precipitating clinical event. The primary outcome was in‐hospital mortality, while secondary outcomes included postoperative complications such as cardiac arrest and acute kidney injury. Echocardiographic indices and laboratory parameters were also evaluated. Multivariable logistic regression analysis was performed to identify independent risk factors associated with in‐hospital mortality. Results: In this study of 4872 patients undergoing CABG, 81.6% had elective and 18.4% had urgent surgery. Urgent CABG was associated with significantly higher in‐hospital mortality compared with elective procedures (6.8% vs. 2.7%, p = 0.01), while the rate of acute kidney injury was similar. In multivariable logistic regression analysis, increasing age, longer cardiopulmonary bypass time, renal dysfunction, and urgent surgery independently increased the risk of in‐hospital mortality, while higher preoperative LVEF was protective. Conclusion: Primary outcome and mortality after CABG are determined by a combination of patient‐ and procedure‐related factors. Older age, renal dysfunction, prolonged cardiopulmonary bypass time, lower preoperative ejection fraction, and urgent surgical status significantly increase the risk of early postoperative death, with urgent CABG more than doubling mortality compared with elective surgery. These findings emphasize the importance of individualized risk assessment, timely referral, optimal preoperative stabilization, and meticulous perioperative management, particularly in high‐risk and urgent cases, to improve short‐term surgical outcomes and reduce in‐hospital mortality.

  • The Effects of Tadalafil on Optical Coherence Tomography, Optical Coherence Tomography Angiography and Ganglion Cell Complex Parameters in Patients with Erectile Dysfunction

    by Mohadeseh Feizi, Shohreh Jafari, Ramin Nourinia, Nastaran Mahmoudnejad, Amirhossein Nayebzadeh, Bahareh Kheiri, Mohammad Hasan Shahriari, Amir Ghaffari Jolfayi, Amirreza Veisi

    To investigate the short and long-term effects of Tadalafil on macular and peri-optic disc choroidal thickness, retinal vascular density, and GCC thickness in patients with erectile dysfunction. Patients with erectile dysfunction who were candidates to treat with 10 mg of Tadalafil every other day and didn't use any type of phosphodiesterase 5 inhibitors (PDE5I) in the previous 6 months and had normal eye exams were included. Macular and peri-optic disc choroidal thickness, superficial and deep retinal vascular density, and Macular Ganglion Cell Complex (GCC) thickness were measured before (baseline), one day, and 3 months after Tadalafil treatment. The measurements before and after treatment were compared. Thirty-one eyes of 16 patients with a mean age of 53.7 (42 to 68) years were included. After Tadalafil consumption, the choroidal thickness in the sub-macular (13.8%) and peri-optic disc (14.9%) area and also the vascular density of superficial (9.6%) and deep (9.8%) retinal capillary plexus was increased on the first day. After 3 months, we found a decremental pattern in all initially increased parameters, although sub-macular and peri-papillary choroidal thickness are yet thicker than the baseline. The retinal ganglion cell complex (GCC) average thickness was not significantly changed, neither on the first day nor after three months. Tadalafil can increase the retinal vascular density and choroidal thickness early after initial consumption but after 3 months the initial increment tend to decrease.


  • The association between metabolic-associated fatty liver diseases and risk of colorectal polyps, neoplasia, and cancer: A systematic review and meta-analysis of over 56 million individuals

    by Amir Azimi, Amir Ghaffari Jolfayi, Vida Rezayifar, Fatemeh Ateen, Hanie Hosseini Fard, San Khasraw Mohammed Mohammed, Hale Hosseinizadeh, Sanam Faizabadi, Ali Keshavarzian, Mohammad Ali Mansournia, et al.


  • Open Access

    Unexpected Heartbreak: A Case Report of Takotsubo Cardiomyopathy Triggered by Electroconvulsive Therapy

    by Faeghe Hosseini, Amir Ghaffari Jolfayi, Mehdi Sheibani

    A 73‐year‐old woman who suffered from major depressive disorder was candidated to receive electroconvulsive therapy (ECT) in combination with medical treatment. Shortly after ECT, she complained of severe chest pain. ECG findings revealed new QRS widening and ST‐segment elevation in anterior leads, and echocardiography revealed anteroapical wall akinesia and reduced ejection fraction. Epicardial coronary arteries were normal in emergent coronary angiography, and the diagnosis of Takotsubo cardiomyopathy was considered. In addition, Troponin I was also elevated. The patient had a good recovery after medical treatment for heart failure, and the ejection fraction in echocardiography improved in a few days. This studied case demonstrates the increasing risk of Takotsubo cardiomyopathy following ECT, which needs special attention for patients with chest pain and ECG abnormalities after ECT.


  • Open Access

    Beyond the Beat, Next‐Generation Sequencing Discovery of Novel RYR2 Gene Variant in Long QT Syndrome

    by Samira Kalayinia, Amir Ghaffari Jolfayi, Amirali Soheili, Majid Maleki, Mohammad Dalili, Mahdieh Soveizi, Saba Komijani

    Background: Long QT syndrome (LQTS) is an inherited cardiac channelopathy marked by QT interval prolongation and increased risk of life‐threatening arrhythmias. While variants in KCNQ1 , KCNH2 , and SCN5A explain most cases, many remain genetically unexplained. This study emphasizes the value of genetic testing in diagnosis and individualized therapy. Methods: A 9‐year‐old boy with recurrent syncope was evaluated for LQTS. Clinical workup included history, physical exam, ECG, echocardiography, exercise testing, electrophysiology studies (EPS), Holter monitoring, and cardiac MRI. Family history was assessed. Genetic testing involved whole‐exome sequencing (WES) and Sanger confirmation, followed by bioinformatic pathogenicity analysis. Results: The boy’s ECG showed a QTc of 470 ms, extending to 500 ms during EPS. No structural cardiac defects were detected. WES revealed a heterozygous missense variant, NM_001035.2:c.12370A > C (p.Ser4124Arg), in the RYR2 gene. In silico tools predicted it to be pathogenic, and Sanger sequencing confirmed it. The variant was also identified in the patient’s mother, who had a history of syncope, but not in the father. The patient responded well to propranolol and remained symptom‐free for 18 months. Conclusion: Identification of a pathogenic RYR2 variant expands the known genetic spectrum of LQTS. The patient’s clinical and familial findings highlight the need to consider RYR2 in genetic testing panels, especially for atypical LQTS cases. Continued research is essential to further clarify the genetics of LQTS and guide targeted management.

  • Imaging findings in cardiovascular involvements of IgG4-related disease: a systematic review study

    by Amir Ghaffari Jolfayi, Alireza Salmanipour, Kiyan Heshmat-Ghahdarijani, Shahla Meshgi, Maedeh Dastmardi, Ghazaleh Salehabadi, Amir Azimi, Mohammad Hossein Mozafary Bazargany, Peyvand Parhizkar Roudsari, Behnaz Mahmoodiyeh, et al.

    Background: Immunoglobulin G4-related disease (IgG4-RD) is a fibroinflammatory condition characterized by IgG4-positive plasma cell infiltration that can affect multiple organs, including the cardiovascular system. The diagnosis of IgG4-RD relies on a combination of clinical, serological, radiological and pathological findings. However, due to the varied and insidious clinical presentations, normal IgG4 levels in a significant percentage of patients and frequent multi-organ involvement, imaging plays a crucial role in the diagnosis of IgG4-RD. The aim of this study is to comprehensively examine the imaging findings in IgG4-related cardiovascular disease for accurate diagnosis and appropriate treatment. Methods: A systematic search was conducted across the electronic databases PubMed, Scopus, Embase and Web of Science, to 1 September 2023, following PRISMA guidelines, searching for studies reporting detailed cardiovascular imaging findings in IgG4-RD. Results: The search yielded 68 studies (60 case reports, 5 case series, 2 cross-sectional, 1 case–control) with 120 cases of cardiovascular IgG4-RD. Most of the cases were male, averaging 62.8 years. The common initial symptoms were dyspnoea and chest pain. The most common imaging finding was vasculopathy, including vessel wall thickening, periarteritits, periaortitis, aortitis, stenosis, ectasia, aneurysm formation, intramural haemorrhage, fistula formation and dissection, followed by pericardial involvement and mediastinal masses. Case series and cross-sectional studies also showed vasculopathy to be the most common finding on various imaging modalities, including angiography and PET/CT, highlighting the complex pathology of IgG4-RD. Conclusion: This study evaluated current IgG4-RD articles, revealing a higher prevalence in men and vasculopathy as the most common cardiovascular complication.